The efficacy of alfuzosin and solifenacin combination in BPH patients with overactive bladder and low flowrate.

Introduction. The alfuzosin and solifenacin combination has previously demonstrated high efficacy and safety in patients with BPH and overactive bladder (OAB), including with severe LUTS, if cases of mechanical type of bladder outlet obstruction (BOO) were excluded. The present study aim was to confirm the efficacy and safety of such combination therapy in patients with severe urinary disorders according to uroflowmetry (UFM). Materials and methods. The observational multicenter AVIATOR study included 208 men with BPH and OAB. Its unique features were: the use of alfuzosin (Alfuprost® MR, 10 mg/day) and solifenacin (Vesigamp, 5 mg/day) combination for 3 months in patients with moderate to severe LUTS; intravesical prostatic protrusion ≥ 10 mm as exclusion criteria; comprehensive assessment of symptoms dynamics by IPSS/QoL, OABSS, PPIUS questionnaires; initial stratification of patients subgroups by Qmax; assessment of changes by UFM report and curve; evaluation of treatment efficacy by «clinically significant response» achieving. Results. Initially, patients were divided into two subgroups, depending on Qmax index: PG1 with Qmax < 12 ml/day (n=102); PG2 with Qmax ≥ 12 ml/day (